1. Generics Bulletin
  2. >>Leadership

Who’s Hired? Alvotech Names New COO After Refiling Adalimumab

As Strides’ Strategy Head Departs And Haggar Becomes Biocon Director

 
• By Dave Wallace

Alvotech has appointed a fresh chief operating officer as it continues to pursue a US approval for its adalimumab biosimilar. Meanwhile, Strides Pharma Science’s strategy head has left the company and Nick Haggar has joined Biocon’s board, while US association the AAM has also welcomed new staff.

Revolving Doors Executives Blurred
The latest executive changes across the off-patent industry • Source: Shutterstock

Alvotech has named a new chief operating officer, representing the latest in a series of management changes for the biosimilars developer as it continues to seek approval for its AVT02 proposed high-concentration interchangeable Humira (adalimumab) rival in the US.

Faysal Kalmoua has now been appointed to the COO role, with the former Synthon and Alvogen executive having served as Alvotech’s head of

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

More from Generics Bulletin